Navigation Links
Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Date:11/12/2012

NATICK, Mass., Nov. 12, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the treatment of systemic lupus erythematosus.

Jennifer Anolik, MD, PhD, Associate Professor of Medicine, Department of Medicine at the University of Rochester (New York), is presenting "Novel nuclear export inhibitors deplete autoreactive plasma cells and protect mice with lupus from nephritis" at the ACR Annual Meeting in Washington DC on November 14 at 12:15 PM in the Concurrent Session on SLE Animal Models.  Dr. Anolik commented, "We are very excited about our findings with Karyopharm's SINE compounds in our mouse lupus models.  These mice develop severe lupus kidney disease which, if untreated, leads to their death.  When we treated the mice with SINE compounds given by mouth, we were able to reduce the level of kidney disease, associated pathogenic autoantibodies, and the plasma cells that produce them.  We are hoping that SINE compounds will be able to move into clinical studies in patients with lupus in the near future."

Dr. Sharon Shacham, Karyopharm's founder, Chief Scientific Officer, and President of research and development commented, "This presentation represents our first public announcement of activity of our novel, oral SINE compounds in an autoimmune disease.  We are particularly excited about Dr. Anolik's work pioneering the use of our compounds to treat mice with severe lupus, and look forward to additional work with her to clarify the key mechanisms responsible for the marked activity she has demonstrated.  We are working with Dr. Anolik and others on plans to evaluate these compounds in humans suffering from lupus and other autoimmune diseases."

About Karyopharm

Founded by Drs. Sharon Shacham and Michael Kauffman in 2009, Karyopharm Therapeutics Inc. has emerged as a leader in t
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
2. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Nile Therapeutics Reports 2011 Third Quarter Financial Results
5. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
6. Fate Therapeutics Strengthens Its iPSC Platform
7. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
10. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
11. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... MADISON, Wis. , July 28, 2014   ... chronic respiratory disease, announced the hire of Brad ... Development. Towle will be responsible for driving the company,s ... "Brad,s broad experience in healthcare, and specifically his past ... valuable insight to the company at this pivotal time ...
(Date:7/28/2014)... 2014  InterMune, Inc. (NASDAQ: ITMN ) ... 2014 financial results at the close of the U.S. ... and webcast will be hosted by InterMune at 4:30 ... investors and others may participate in the conference call ... ID#21728775. A replay of the webcast and teleconference will be ...
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market ... the Canada Endoscopy Visualization Systems market. The report ... (in units) and average prices (in US dollars) ... Mid-Range Endoscopy Visualization Systems and Low-End Endoscopy Visualization ... . , The report also provides company shares ...
(Date:7/25/2014)... from the University of Leicester has furthered our ... potential to create new materials using nanosized ,building ... in the prestigious academic journal Physical Review ... examine in rich detail the structure and internal ... acetylene molecule and a single helium atom. , ...
Breaking Biology Technology:Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2InterMune to Release Second Quarter Financial Results on August 6 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3
... 2008 Lentigen Corporation today,announced an exclusive ... for licensing technologies from the University of,Cambridge ... area of lentiviral vector,technology. The technology was ... at the University of Cambridge., "The ...
... Vice President of Finance -, HOPKINTON, Mass., April ... ) today announced the promotion of Peter F.,McAree to ... as Vice President of Finance at Caliper. Effective April,4, ... CFO., McAree has more than 20 years of ...
... Chairman and CEO Honors the Anniversary by Ringing The Closing Bell(R) ... ... Calif., April 3, 2008 Edwards,Lifesciences Corporation (NYSE: EW ), ... today announced its,50th anniversary of partnering with clinicians to develop life-saving,innovations. ...
Cached Biology Technology:Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge 2Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge 3Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
(Date:7/25/2014)... PITTSBURGH -- The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... the UPMC/UPCI Multidisciplinary Thyroid Center and other diagnostic ... the correct initial surgery by 30 percent, according ...
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... DALLAS May 20, 2008 Mutations in two ... the brain involved in sleep create a human-like insomnia ... found. The findings may help scientists better understand the ... This is one of the most dramatic ...
... exposure to chemicals is on the increase. From food ... with potentially-toxic substances could be affecting our health ... Nottingham are set to take part in one of ... on female mammals. Part of the Reproductive Effects of ...
... CITY Researchers have been unable to build an ... dream of ultrafast optical computers. But now, University of ... photonic crystals with the ideal, diamond-like structure: They are ... beetle from Brazil. It appears that a simple ...
Cached Biology News:Gene mutations in mice mimic human-like sleep disorder, UT Southwestern researchers find 2Do chemicals in the environment affect fertility? 2The photonic beetle 2The photonic beetle 3The photonic beetle 4The photonic beetle 5
... Rabbit polyclonal antibody to human XAB2 ... was first identified through its interaction with ... a fraction of XAB2 interacts with the ... well as with RNA polymerase II. Microinjection ...
... provide custom microplate coating using advanced automated high throughput microplate ... formats. We can also accommodate virtually any lot size of ... , 8 and 12 ... 384 well microplate, ...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: